Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Jacobson

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|September 30, 1990
Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trialG S Leoung, D W Feigal, A B Montgomery, et al.
AIDS (London, England)|April 1, 1994
Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious DiseasesM A Jacobson, M Wulfsohn, J E Feinberg, et al.
The Journal of Infectious Diseases|July 1, 1994
Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151M A Jacobson, F Kramer, Y Bassiakos, et al.
The Journal of Infectious Diseases|December 1, 1994
Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trialsC Flexner, C van der Horst, M A Jacobson, et al.
AIDS (London, England)|July 1, 1995
The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudineM A Jacobson, V De Gruttola, M Reddy, et al.
AIDS (London, England)|March 1, 1997
Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovirA J Mueller, M A Jacobson, S Hurwitz, et al.
The Journal of Infectious Diseases|November 1, 1991
Natural history of disseminated Mycobacterium avium complex infection in AIDSM A Jacobson, P C Hopewell, D M Yajko, et al.
The Journal of Infectious Diseases|September 1, 1992
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitisM M Reddy, M H Grieco, G F McKinley, et al.
The Journal of Infectious Diseases|February 1, 1994
Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infectionD P Chin, P C Hopewell, D M Yajko, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|September 30, 1990
Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trialG S Leoung, D W Feigal, A B Montgomery, et al.
AIDS (London, England)|April 1, 1994
Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious DiseasesM A Jacobson, M Wulfsohn, J E Feinberg, et al.
The Journal of Infectious Diseases|July 1, 1994
Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151M A Jacobson, F Kramer, Y Bassiakos, et al.
The Journal of Infectious Diseases|December 1, 1994
Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trialsC Flexner, C van der Horst, M A Jacobson, et al.
AIDS (London, England)|July 1, 1995
The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudineM A Jacobson, V De Gruttola, M Reddy, et al.
AIDS (London, England)|March 1, 1997
Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovirA J Mueller, M A Jacobson, S Hurwitz, et al.
The Journal of Infectious Diseases|November 1, 1991
Natural history of disseminated Mycobacterium avium complex infection in AIDSM A Jacobson, P C Hopewell, D M Yajko, et al.
The Journal of Infectious Diseases|September 1, 1992
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitisM M Reddy, M H Grieco, G F McKinley, et al.
The Journal of Infectious Diseases|February 1, 1994
Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infectionD P Chin, P C Hopewell, D M Yajko, et al.
HIV Clinical Trials|July 28, 2009
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030D A Wohl, M A Kendall, J Andersen, et al.
Pageof 15